We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

LabCorp to Acquire Certain Assets of Quest Diagnostics

By HospiMedica staff writers
Posted on 03 Mar 2003
Under an agreement made in early February 2003, Laboratory Corp. of America (LabCorp, Burlington, NC, USA) agreed to pay US$4.5 million for certain assets of Quest Diagnostics (Teterboro, NJ, USA), following the completion of Quest's acquisition of Unilab Corp. (Tarzana, CA, USA). Quest's acquisition of Unilab for $813 million was recently approved by US regulators and is now completed.

The LabCorp purchase is designed to satisfy the concern of regulators that Quest's purchase of Unilab might harm competition of laboratory services in northern California. The assets LabCorp is acquiring include the leases for 46 patient service centers and contracts with independent physician associations in California (USA). LabCorp has been a pioneer in commercializing new diagnostic technologies and said it is the first US clinical laboratory to fully embrace genomic testing.

LabCorp combines its expertise in clinical testing technology with its Centers of Excellence. These include the Center for Molecular Biology and Pathology (Research Triangle Park, NC, USA), its National Genetics Institute in Los Angeles (CA, USA), its Center for Esoteric Testing (Burlington, NC, USA), and its ViroMed center in Minneapolis (MN, USA). The company had revenues of $2.2 billion in 2001.

"Strategically, the business acquired in this very important market also provides LabCorp with a solid foundation for generating additional revenues through both the routine physician market as well as business development activities in esoteric testing,” said Richard L. Novak, executive vice president and CEO of LabCorp.




Related Links:
LabCorp
Quest Diagnostics

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automated Staining Unit
RAL Stainer

Latest Industry News

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
03 Mar 2003  |   Industry

Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
03 Mar 2003  |   Industry

New Collaboration to Advance Microbial Identification for Infectious Disease Diagnostics
03 Mar 2003  |   Industry